Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 2Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 16Recruiting 14Terminated 9Active not recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 36Leukemia, Myeloid, Acute 27Colorectal Neoplasms 27Neoplasms 26Neoplasm Metastasis 22Recurrence 21Multiple Myeloma 20Advanced Solid Tumors 20Lymphoma, B-Cell 19Breast Neoplasms 18Pancreatic Neoplasms 14Lung Neoplasms 13Glioblastoma 13Carcinoma, Hepatocellular 13Lymphoma 12Brain Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Hematologic Neoplasms 11Glioma 11Squamous Cell Carcinoma of Head and Neck 10Ovarian Neoplasms 10Melanoma 10Leukemia 10Advanced Solid Tumor 10Triple Negative Breast Neoplasms 9Prostatic Neoplasms 9Head and Neck Neoplasms 9Lymphoma, Non-Hodgkin 8Esophageal Neoplasms 8Myelodysplastic Syndromes 7

Interventions

futibatinib 1Taxes 1Specimen Handling 1Ramucirumab 1Paclitaxel 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × Adenocarcinoma Of Esophagus × Clear all
NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Northwestern University

Phase 1 Not yet recruiting
18 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡